AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00894725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left colonic resection
Description: conventional open colonic resection
Study NCT03974490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation
Description: Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
Study NCT01992471 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pre-test Assessment
Description: Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
Study NCT02918981 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
Study NCT02918981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
Study NCT02918981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
Study NCT02918981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 14 g Whey protein
Study NCT01992471 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pre test Counseling
Description: Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
Study NCT00834444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study NCT00834444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famvir® 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study NCT00549822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
Study NCT03319108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Pulmonary Rehabilitation Program for 8 weeks
Study NCT04365387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab will be administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
Study NCT04365387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
Study NCT02254005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study NCT04353362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: 400 mg, 1 time per day for 5 days
Study NCT04353362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 500 mg, 3 times per day for 7 days
Study NCT04353362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg, 3 times per day, for 7 days
Study NCT01747668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Prenatal Vitamin soft-gel capsule
Description: One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
Study NCT01747668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Description: Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
Study NCT01747668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Description: Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
Study NCT04168398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Anticoagulation
Study NCT02222064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
Study NCT00747305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00747305 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00747305 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00747305 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study NCT01992471 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
Study NCT01992471 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-test counseling, and post-test assessment
Description: When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
Study NCT00747305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00747305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01992471 — intervention group
Intervention type: BEHAVIORAL
Intervention: Follow-up assessments (6 and 12 months)
Description: At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
Study NCT00422461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral, tablets, once daily, for 28 days
Study NCT00747305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00747305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00747305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT03220958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 20mg
Study NCT03220958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 25mg
Study NCT03220958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 100ml normal saline
Study NCT03220958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100ml normal saline
Study NCT02742194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dry extract of ginger
Description: Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
Study NCT02742194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
Study NCT02584907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Enteral Nutrition
Description: Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
Study NCT00422461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
Study NCT00422461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 4 mg, oral, tablets, once daily, for 28 days
Study NCT00422461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 10 mg, oral, tablets, once daily, for 28 days
Study NCT04633304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EndoAVF System for endovascular AV fistula creation
Description: AV fistula creation
Study NCT04242602 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler
Description: Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
Study NCT00908388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE TAG® Thoracic Endoprosthesis
Description: Endoprosthetic Implant
Study NCT00832962 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Whole blood sample
Study NCT00832962 — intervention group
Intervention type: OTHER
Intervention: Usual prophylaxis
Description: Prophylactic anti-RhD
Study NCT01217138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine autoinjector
Description: We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
Study NCT01217138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Epinephrine autoinjector
Description: We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
Study NCT04250389 — intervention group
Intervention type: OTHER
Intervention: Hemodynamic assessment (micro and macrocirculatory)
Description: Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases.
Study NCT00374985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Oxaliplatin
Description: weekly doses
Study NCT00374985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: regular fractions
Study NCT02131493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1, Gemcitabine
Study NCT02131493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Gemcitabine
Study NCT00710788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer phosphate-binders
Description: 1600 mg/day for 2 years
Study NCT00710788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate 1 g/day for 2 years
Study NCT01498666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri protectis
Description: 1 tablet once daily for 4 weeks
Study NCT01498666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet once daily for 4 weeks
Study NCT04802915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative ERM and ILM staining with their assessment and removal
Description: ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
Study NCT00170755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
Study NCT02269943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Study NCT02136485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Description: 8 sessions of MBSR
Study NCT02136485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: waiting list control
Study NCT00598481 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Therapy
Description: Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
Study NCT03798457 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: In this study there is no intervention
Study NCT02435264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthier Dining Program Intervention
Description: The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
Study NCT00425308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus + Cyclosporine
Study NCT00425308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
Study NCT00425308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study NCT02918981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.6 g Whey protein + 1.25 g leucine
Study NCT02918981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides
Study NCT02918981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline
Study NCT02918981 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water control
Study NCT01050478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: paliperidone ER at 2 dosage levels (6 and 9 mg/day)
Study NCT01050478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Description: Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
Study NCT05629000 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid revascularization
Description: All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
Study NCT05629000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-PWI
Description: Multi-modal MRI before and after surgery.
Study NCT05629000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTA
Description: CTA before and after surgery.
Study NCT01852721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Men and Mediterranean diet
Description: The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
Study NCT01852721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Women and Mediterranean diet
Description: Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
Study NCT01111448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
Study NCT04188392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: pimavanserin tablet
Study NCT01440179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
Study NCT02588144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: [standard STN]
Description: High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
Study NCT02588144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: [STN+SNr]
Description: high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
Study NCT01727427 — intervention group
Intervention type: DRUG
Intervention: Heparin, fondaparinux, vitamin-K antagonists, aspirin
Description: Parenteral or oral anticoagulant Antiplatelet agent
Study NCT01161121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
Study NCT01161121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
Study NCT05629000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: PET/MRI before surgery.
Study NCT05629000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound before and after surgery.
Study NCT04112498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: relatlimab
Description: Specified dose on Specified days
Study NCT04112498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days
Study NCT04112498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on Specified days